Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06921928 · ClinicalTrials.gov registry record · Phase 1

Study for AZD4360 in Participants With Advanced Solid Tumours

A Phase 1 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
117
Enrollment target
17
Study locations

NCT06921928 is a Phase 1 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 117 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (63% lower). The trial reports 17 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06921928, a Phase 1 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
117 participants
Enrollment target
17
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.

Conditions Studied

Gastric Cancer Pancreatic Ductal Adenocarcinoma Biliary Tract Cancer Gastroesophageal-junction Cancer

Interventions

  • DRUG AZD4360

Study Locations (17)

Other

  • Research Site - Beijing
  • Research Site - Chengdu
  • Research Site - Shanghai
  • Research Site - Wuhan
  • Research Site - Berlin
  • Research Site - Dresden
  • Research Site - Frankfurt
  • Research Site - Chūōku
  • Research Site - Kashiwa
  • Research Site - Kōtoku
  • Research Site - Glasgow
  • Research Site - Leeds
  • Research Site - London
  • Research Site - Oxford

California

  • Research Site - Santa Monica

Rhode Island

  • Research Site - Providence

Texas

  • Research Site - Houston

Trial Details

FieldValue
Enrollment Target 117 participants
Start Date 2025-04-29
Est. Completion 2027-12-16
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06921928

The ClinicalTrials.gov registry entry for NCT06921928 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (63% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which AZD4360 is the first listed.

NCT06921928 reports 17 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Rhode Island.

Frequently Asked Questions

What is clinical trial NCT06921928 about?

NCT06921928 is a clinical study titled "Study for AZD4360 in Participants With Advanced Solid Tumours". The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.

What is the current status of trial NCT06921928?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2025-04-29. Estimated completion is 2027-12-16.

What conditions does trial NCT06921928 study?

This clinical trial studies the following conditions: Gastric Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer, Gastroesophageal-junction Cancer.

What interventions are being tested in trial NCT06921928?

The interventions under investigation include: AZD4360 (DRUG).

Who is sponsoring clinical trial NCT06921928?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06921928 being conducted?

This trial has 17 study locations across California, Rhode Island, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

Pancreatic Ductal Adenocarcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.